Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 14/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | ADK | P55263 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931806 | 1.00 | FURIN (0.55) | FURINGPR119PGK1ADKCKS1B | |
| SCHEMBL29890947 | 1.00 | FURIN (0.55) | FURINGPR119PGK1ADKCKS1B | |
| SCHEMBL21555640 | 0.95 | FURIN (0.50) | FURINGPR119PGK1ADKCKS1B | |
| SCHEMBL30931861 | 0.95 | FURIN (0.50) | FURINGPR119PGK1ADKCKS1B | |
| SCHEMBL29890819 | 0.95 | FURIN (0.50) | FURINGPR119PGK1ADKCKS1B | |
| SCHEMBL21564422 | 0.92 | FURIN (0.54) | FURINGPR119PGK1ADKCKS1B | |
| SCHEMBL21551754 | 0.91 | FURIN (0.53) | FURINGPR119PGK1ADKCKS1B | |
| SCHEMBL30931829 | 0.91 | FURIN (0.53) | FURINGPR119PGK1ADKCKS1B | |
| SCHEMBL29890982 | 0.91 | FURIN (0.53) | FURINGPR119PGK1ADKCKS1B | |
| SCHEMBL21551434 | 0.89 | GPR119 (0.53) | FURINGPR119PGK1ADKCKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| CN-112384509-A | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-02-19 | — | — | CN | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
| US-9388132-B2 | Isobaric tandem mass tags for quantitative proteomics and peptidomics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | FURIN 1/4885GPR119 2318/4885PGK1 2564/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | FURIN 1/4885GPR119 2318/4885PGK1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.